2F5.F Scinai Immunotherapeutics Ltd.

Healthcare Biotechnology Frankfurt Exchange
0.2260 EUR
Close of Nov 11, 2026
0.2020 2.40
Market cap
EUR 117K
P/E
0.0x
P/B
0.56x
ROE
26.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2F5.F undervalued?

Graham number

The Graham number of Scinai Immunotherapeutics Ltd. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scinai Immunotherapeutics Ltd. fundamental analysis

No fundamental analysis for Scinai Immunotherapeutics Ltd. yet.

Scinai Immunotherapeutics Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract develo…

Full company profile